FTC settles Hikma Roxane competition concerns
The US Federal Trade Commission (FTC) has approved a final order settling charges that pharmaceutical company Hikma’s buyout of Roxane Laboratories and Boehringer Ingelheim Roxane would be anticompetitive.
The FTC made the announcement yesterday, May 5. The order was approved in a 3-0 vote.
Under the terms of the order, Hikma must sell the rights and assets to two generic drugs, prednisone tablets and lithium carbonate capsules, to Renaissance Pharma.
Hikma is also required to relinquish its rights to market Tambocor (flecainide acetate) tablets in the US and sell its equity interest in its drug development partner, India-based Unimark Remedies.
Under the order, Hikma has 20 days to comply with the terms.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk